Antiarrhythmic agents and proarrhythmia

Critical Care Medicine

Volumn 28, Issue 10 SUPPL., 2000, Pages

  Chaudhry, G M ^a   Haffajee, C I ^a  

^a ST ELIZABETH'S MEDICAL CENTER   (United States)

Author keywords

Antiarrhythmia agents; Arrhythmias; Supraventricular tachycardia; Ventricular tachycardia

Indexed keywords

ADENOSINE; AMIODARONE; ANTIARRHYTHMIC AGENT; AZIMILIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRETYLIUM; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DILTIAZEM; DISOPYRAMIDE; DOFETILIDE; ELECTROLYTE; FLECAINIDE; IBUTILIDE; ISOPRENALINE; LIDOCAINE; MAGNESIUM; MEXILETINE; MORACIZINE; PHENYTOIN; PROCAINAMIDE; PROPAFENONE; QUINIDINE; SODIUM CHANNEL BLOCKING AGENT; SOTALOL; TOCAINIDE; VERAPAMIL;

CLINICAL TRIAL; DEFIBRILLATOR; HEART ARRHYTHMIA; HOLTER MONITORING; HUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0033790606     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-200010001-00008     Document Type: Review

References (58)

1. Classification of antiarrhythmic drugs
2. The Sicilian gambit: A new approach to classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms
3. Current antiarrhythmic drugs: An overview of mechanisms of action and potential clinical utility
4. Antiarrhythmic agents: The modulated receptor mechanism of action of sodium and calcium channel blocking drugs
5. The molecular and ionic specificity of antiarrhythmic drug actions
6. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias
7. A randomized comparison of electrophysiologic study to electrocardiographic monitoring for prediction of antiarrhythmic drug efficacy in patients with ventricular tachyarrhythmias
8. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion
9. Quinidine-related mortality in the short-to-medium term treatment of ventricular arrhythmias: A meta-analysis
10. + channel blockade and to increases in heart rate
11. Effect of lidocaine on atrioventricular response in atrial fibrillation associated with the Wolff-Parkinson-White syndrome
12. Effects of encainide, flecainide, imipramine and moricizine on ventricular arrhythmias during the year after acute myocardial infarction: The CAPS
13. Mortality and morbidity in patients receiving encainide, flecainide or placebo
14. Preliminary results of the cardiac arrest study Hamburg (CASH)
15. Effects of flecainide in patients with new SCN5A mutation: Mutation-specific therapy for long QT syndrome?
16. Hybrid pharmacologic and ablative therapy: A novel and effective approach for the management of atrial fibrillation
17. Radiofrequency ablation of atrial flutter due to administration of class IC antiarrhythmic drugs for atrial fibrillation
18. Radiofrequency ablation of 'class IC atrial flutter' in patients with resistant atrial fibrillation
19. Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation
20. Randomized double-blind comparison of intravenous amiodarone and bretylium in the treatment of patients with recurrent, hemodynamically destabilizing ventricular tachycardia or fibrillation
21. Randomised trial of effect of amiodarone on mortality in patients with left ventricular dysfunction after recent myocardial infarction: EMIAT
22. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarizations: CAMIAT
23. Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias
24. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia (CHF STAT)
25. Randomised trial of low-dose amiodarone in severe congestive heart failure
26. A randomized study of the prevention of sudden death in patients with coronary artery disease
27. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia
28. Controlled trial of sotalol for one year after myocardial infarction
29. Effects of d-sotalol on mortality in patients with left ventricular function after recent and remote myocardial infarction
30. Double-blind trial of lignocaine versus sotalol for acute termination of spontaneous sustained ventricular tachycardia
31. Amiodarone to prevent recurrence of atrial fibrillation
32. Sotalol versus quinidine for maintenance of sinus rhythm after DC cardioversion of atrial fibrillation
33. Effectiveness of sotalol in preventing supraventricular tachyarrhythmias shortly after coronary artery bypass grafting
34. Ibutilide and the treatment of atrial arrhythmias: A new drug - Almost unheralded - Is now available to US physicians
35. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation
36. Comparison of the cost of transthoracic cardioversion of atrial fibrillation with and without ibutilide pretreatment
37. Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment
38. Intravenous dofetilide: A class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter
39. Efficacy and safety of oral dofetilide in maintaining normal sinus rhythm in patients with atrial fibrillation/flutter: A multicenter study
40. Pharmacology of azimilide dihydrochloride (NE-10064), a class III antiarrhythmic agent
41. Effects of calcium ions and local anaesthetics on electrical properties of Purkinje fibers
42. Basic concepts in cellular cardiac electrophysiology: Block of ion channels by antiarrhythmic drugs
43. Differential analysis of frequency-dependent effects of class I antiarrhythmic drugs according to periodic ligand binding: Implications for antiarrhythmic and proarrhythmic efficacy
44. Paroxysmal ventricular fibrillation with cardiac recovery in a case with auricular fibrillation and complete heart block while under quinidine sulfate therapy
45. Quinidine syncope: Paroxysmal ventricular fibrillation occurring during treatment of chronic atrial arrhythmias
46. Meta-analytic evidence against prophylactic use of lidocaine in acute myocardial infarction
47. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation
48. Risks and benefits of antiarrhythmic therapy
49. The long QT syndromes: A critical review - New clinical observations and a unifying hypothesis
50. Approaches to sudden death from coronary heart disease
51. Incidence, type and dose dependence of proarrhythmic events during sotalol therapy in patients treated for sustained VT/VF
52. Malignant ventricular tachyarrhythmias associated with the use of encainide
53. Clinical and electrophysiological assessment of oral flecainide acetate for recurrent ventricular tachycardia: Evidence for exacerbation of electrical instability
54. Flecainide induced ventricular tachycardia and fibrillation in patients treated for atrial fibrillation
55. Reversal of proarrhythmic effects of flecainide acetate and encainide hydrochloride by propranolol
56. Risk of initiating antiarrhythmic drug therapy for atrial fibrillation in patients admitted to a university hospital